Stuart B. Padnos Professor of Breast Cancer Research Clinical Director, Breast Oncology Program University of Michigan Ann Arbor, Michigan
The North American Breast Cancer Group (NABCG) has prospectively collected and stored breast cancer tissues, blood, serum, and DNA from patients who participated in clinical trials for studies of new or promising tumor markers. A Correlative Science Committee (CSC) decides which should go forward. BCRF has supplied support for ongoing activities of the CSC, including approved studies, infrastructure projects related to archived specimens, and collaborations with the Breast International Group (BIG).
Over the past year, at least 15 papers and reports at major scientific meetings have been published by funded investigators. Inventories of the archived tissues are now publicly available, and these specimens have been centrally evaluated for estrogen receptor (ER), progesterone receptor (PR) and the HER2 protein. Major workshops have led to initiatives within the NABCG for pharmacogenomics, to standardize assays for an important biomarker, called Ki67, and to plan correlative sciences for a major trial, the TAILORx study.
In the coming year the NABCG will continue to provide support to investigators and cooperative groups whose concepts are approved by the NABCG CSC, and to the Breast International Group to further support their translational science activities.
In a separate BCRF study with Co-PI James M. Rae, Dr. Hayes is focused on identifying genetic markers that will be able to predict whether an individual patient will respond to and tolerate specific anti-estrogen breast cancer therapies. Anti-estrogen therapies such as tamoxifen and aromatase inhibitors have dramatically improved outcomes in breast cancers that have the estrogen receptor (ER+). Not all women with ER+ tumors, however, will respond to these therapies and some may experience a cancer recurrence after treatment. To this end, Drs. Hayes and Rae have been analyzing archived (stored) DNA from two of the largest clinical trials that tested the efficacy and safety of tamoxifen and aromatase inhibitors (AIs), the "Intergroup Exemestane Study" (IES) and the "Arimidex, Tamoxifen, Alone or in Combination" Trial (ATAC). The value of these samples comes from the long-term follow up and comprehensive clinical outcomes data that will allow the investigators to identify possible gene variants associated with response to anti-estrogen therapy. These studies will facilitate important gene-based drug discoveries and lead to more personalized treatment of breast cancer.
Daniel Hayes, MD is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (UMCCC) and the Stuart B. Padnos Professor of Breast Cancer Research. He received a AB (1974) and a MS (1977) at Indiana University, his MD from the Indiana University School of Medicine (1979), a residency in Internal Medicine at the UTHSC, Dallas, Texas (Parkland Memorial Hospital, 1979-1982), and a fellowship in Medical Oncology at Harvard’s Dana Farber Cancer Institute (DFCI, 1982–1985). From 1992–1996, he was Medical Director of the Breast Evaluation Center at DFCI. In 1996, he moved to the Georgetown University Lombardi Cancer Center, and he joined the UMCCC in 2001. Dr. Hayes has a national and international reputation in the field of experimental therapeutics targeted to breast cancer, working on serum and tissue markers such as HER-2, circulating tumor cells and pharmacogenomics which have prognostic and/or predictive value in the treatment of breast cancer.